albumin - publications

Predict more albumin - ligand interactions now!



Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model.


Mol Pharm. 2013 Mar 8;


Authors: Zsila F


Abstract

According to the conventional view, non-covalent association of small molecules with human serum albumin (HSA) occurs principally at the so called Sudlow's sites located in subdomain IIA and IIIA. By employing a circular dichroism (CD) spectroscopic approach it is shown that biliverdin is a specific CD label of an additional drug binding area in subdomain IB. CD competition experiments disclosed the entrapment of a diverse assortment of acidic, neutral and basic molecules within subdomain IB including anticancer drugs (camptothecin, doxorubicin, daunorubicin, teniposide, suramin, tyrosine kinase inhibitors), anticoagulants (dicoumarol), various steroid agents (bile acids, carbenoxolone), nonsteroidal antiinflammatory drugs, natural substances (aristolochic acid, glycyrrhetinic acid) and synthetic dyes (methyl orange, azocarmine B). These finding imply that subdomain IB can be considered as the third major drug binding region of HSA featured with promiscuous ligand recognition ability. Additionally, subdomain IB is allosterically coupled with the Sudlow's sites, the ligand binding of which is shown to alter the HSA binding mode and affinity of biliverdin and hemin. Brief case studies are presented to illustrate how the evaluation of spectral changes of tetrapyrrole CD probes gains new insight into the HSA binding properties of endogenous as well as pharmaceutical agents.

PMID: 23473402 [PubMed - as supplied by publisher]